logo
Plus   Neg
Share
Email

Acceleron Pharma's ACE-083 Fails In Phase 2 Study For FSHD

Acceleron Pharma Inc. (XLRN) on Monday said its investigational therapy ACE-083 for the treatment of facioscapulohumeral muscular dystrophy (FSHD) did not achieve functional secondary endpoints in the Phase 2 trial.

Although ACE-083 showed a significant increase in mean total muscle volume, which was the primary endpoint of the trial, the secondary endpoint of functional tests was failed. As a result, the company is not planning to continue with further study of ACE-083 for FSHD.

FSHD is a genetic muscle disorder that starts usually before the age of 20. It first affects the muscles of the face, shoulder blades and upper arms by weakening them, and gradually spreads to other muscles.

ACE-083 is also being explored as a potential treatment for Charcot-Marie-Tooth disease—a neuromuscular disorder, and a phase II trial in this indication is underway. Topline results from this trial are expected in the first quarter of the next year.

XLRN closed Monday's trading at $44.65, up 1.71%. In after-hours, the stock was down 6.83% to $41.60.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Back-to-school and college spending is projected to exceed the $100 billion mark for the first time ever ever despite the coronavirus pandemic, according to an annual survey by the National Retail Federation or NRF. The survey released by NRF and Prosper Insights & Analytics projects total spending for K-12 and college combined to reach $101.6 billion in 2020, up from last year's $80.7 billion. U.S. laboratory equipment maker Thermo Fisher Scientific Inc. (TMO) and Netherlands-based Qiagen N.V. (QGEN) announced Thursday that they have entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of Qiagen. The... Morgan Stanley (MS) reported better-than-expected Q2 results, bolstered by strong trading revenues, amid the COVID-19 pandemic.
Follow RTT